The IL18 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the HT29 human colorectal adenocarcinoma line, with targeted gene disruption at the IL18 locus. This heterogeneous pool of edited cells serves as a loss-of-function model to interrogate interleukin-18 biology without the constraints of clonal isolation, providing a robust system for studying IL-18-dependent mechanisms in a physiologically relevant epithelial context.
The HT29 host cell line, established from a 44-year-old Caucasian female with colon adenocarcinoma, is a widely utilized intestinal epithelial model exhibiting tumorigenic properties. HT29 cells retain key characteristics of colorectal adenocarcinoma, including the ability to form polarized monolayers and express junctional proteins, making them a valuable platform for investigating inflammation-driven oncogenesis and mucosal immunity.
IL-18 is a pleiotropic proinflammatory cytokine that is proteolytically activated by caspase-1 following NLRP3/ASC inflammasome assembly. Upon secretion, IL-18 binds the heterodimeric receptor complex composed of IL18R1 and IL18RAP, initiating MYD88-dependent signal transduction. This triggers downstream recruitment of IRAK1 and TRAF6, leading to TAK1-mediated phosphorylation cascades that activate the IKK complex, NF-??B, and MAPK1/3 pathways. IL-18 signaling culminates in the transcriptional induction of key immune effectors such as interferon-gamma (IFNG), tumor necrosis factor (TNF), interleukin-8 (IL8), and chemokine CCL2, as well as adhesion molecule ICAM1. Negative regulation is exerted by the soluble decoy receptor IL18BP. Upstream, IL-18 expression is induced by NF-??B and IRF1 in response to Toll-like receptor ligands like lipopolysaccharide and NLRP3 inflammasome activators.
In the HT29 colorectal cancer background, IL-18 knockout cells offer a powerful tool to dissect the cytokine’s contributions to tumor-promoting inflammation, intestinal barrier dysfunction, and immune cell recruitment. IL-18 is implicated in inflammatory bowel disease and colorectal cancer progression, where it can drive Th1 responses and enhance NK cell cytotoxicity. Disrupting IL-18 in this epithelial model allows researchers to separate epithelium-intrinsic effects from paracrine signaling in the tumor microenvironment, bridging innate and adaptive immunity.
These polyclonal knockout cells are optimized for a range of experimental applications, including western blotting and RT-qPCR to confirm gene disruption and downstream target modulation, ELISA-based measurement of IL-18 secretion loss, NF-??B reporter assays, and phospho-specific analysis of MAPK pathway activation. Additional applications encompass cell proliferation, migration, and invasion studies, as well as co-culture setups with immune effector cells to evaluate cytokine crosstalk. Cytokine profiling and caspase-1 activity assays further complement mechanistic investigations. This product is suitable for drug target validation and functional genomics screening. For technical inquiries, please contact Ascent Research.
